A study of oxidative stress and the newer antiepileptic drugs in epilepsy associated with severe motor and intellectual disabilities

详细信息    查看全文

• 作者：Masahito Morimoto^a ; ^b ; ^{morimoto@hinomine-mrc.jp} ; Shigeko Satomura^b ; Toshiaki Hashimoto^b ; Shojiro Kyotani^a
• 关键词：antiepileptic drugs ; children with disabilities ; epilepsy ; oxidative stress
• 刊名：Journal of the Chinese Medical Association
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：80
• 期：1
• 页码：19-28
• 全文大小：2910 K
• 卷排序：80

文摘

Patients with severe motor and intellectual disabilities (SMID) are those who have both severe intellectual disabilities and severe physical disabilities. Intractable epilepsy is often associated with SMID. The purpose of this study was to elucidate the relationship between epilepsy associated with SMID and oxidative stress, and to clarify the safety and efficacy of the newer antiepileptic drugs (newer AEDs), lamotrigine and levetiracetam.MethodsThis study was conducted in 27 SMID patients with epilepsy who were treated with the newer AEDs. The patient characteristics and the safety and efficacy of the newer AEDs were investigated. The reactive oxygen metabolite (d-ROM) and biological antioxidant potential (BAP) levels were measured as indicators of the degree of oxidative stress. The relationship between the investigation results (the patient characteristics, and the safety and efficacy of the newer AEDs) and the results of measurements of the d-ROMs/BAP were analyzed.ResultsAll the patients who discontinued the newer AEDs had abnormal plasma d-ROM levels. In addition, all the patients who developed adverse events also had abnormal d-ROM levels. Furthermore, there was a trend toward a lower response rate in patients with higher plasma d-ROM levels.ConclusionThe results of this study suggested that d-ROM levels are useful for predicting the safety and efficacy of the newer AEDs (lamotrigine, levetiracetam) in SMID patients with intractable epilepsy. Therefore, d-ROMs could be important biomarkers for determining the safety and efficacy of drug therapy in SMID patients with epilepsy.